Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on May 6, 2025
Duos Technologies Group Sets First Quarter 2025 Earnings Call for Thursday, May 15, 2025 at 4:30 PM ET
GlobeNewswire
·
May 6, 2025
JACKSONVILLE, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT) will hold a conference call on Thursday, May 15, 2025 at 4:30 p.m. Eastern time to discuss its financial results for the first …
ZenaTech Expands Ireland Office Offering Drone as a Service (DaaS) Including Precision Agriculture to a European Market Growing at 28.6% Annually
GlobeNewswire
·
May 6, 2025
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS, and …
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study
GlobeNewswire
·
May 6, 2025
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of …
Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
GlobeNewswire
·
May 6, 2025
GAL-101 well tolerated; excellent safety and pharmacokinetic profile strongly supports oral administration Next arms of study, including multiple ascending dose (MAD), underway and expected to complete in late 2025 Planned indications include dry age- …
Lingokids puts Parent Guilt on Trial in First of its Kind Campaign
GlobeNewswire
·
May 6, 2025
LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- Today, Lingokids, the #1 interactive app for kids aged 2-8, puts the parenting screen time debate on trial with the launch of its largest U.S. campaign, The Trial by Lingokids. The campaign film highlights the …
Coralogix Launches Advanced Continuous Profiling to Accelerate Issue Resolution Without Slowing Production
GlobeNewswire
·
May 6, 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Coralogix, the first cross-stack observability platform provider, today announced Continuous Profiling, an advanced capability that delivers unparalleled real-time visibility into application performance without any …
VAXIL: SHARE CONSOLIDATION
GlobeNewswire
·
May 6, 2025
Not for distribution by US newswire or in United States TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to make the following updates regarding the Company’s activities. Vaxil announces …
PeerGame Introduces Seamless Crypto Transactions with WalletConnect Integration
GlobeNewswire
·
May 6, 2025
London, UK, May 06, 2025 (GLOBE NEWSWIRE) -- Leading cryptocurrency gaming company PeerGame has announced the launch of its new cashier system - its platform will now be integrated with WalletConnect for seamless, secure, and fast crypto transactions. The …
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
GlobeNewswire
·
May 6, 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025. Altimmune management …
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire
·
May 6, 2025
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. …
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
GlobeNewswire
·
May 6, 2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of …
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 6, 2025
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on …
Bioventus Reports First Quarter Financial Results
GlobeNewswire
·
May 6, 2025
Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0% First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year period Non-GAAP earnings* of $0.08 per share increased 33% Company reiterated …
Neuronetics Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of …
Kraig Biocraft Laboratories Successfully Completes March/April Production Cycle; May Production Now Underway
GlobeNewswire
·
May 6, 2025
ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk …
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
GlobeNewswire
·
May 6, 2025
Cost-saving initiatives expected to extend company’s cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results …
ARRAY Technologies, Inc. Reports Financial Results for the First Quarter 2025
GlobeNewswire
·
May 6, 2025
2025 First Quarter Highlights Revenue of $302.4 million Gross Margin of 25.3% Adjusted gross margin(1) of 26.5% Net income to common shareholders of $2.3 million Adjusted EBITDA(1) of $40.6 million Net income per basic and diluted share of $0.02 Adjusted …
Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients
GlobeNewswire
·
May 6, 2025
TPM502 achieved significant and dose-dependent reduction in IL-2 and IFN-γ release by gluten-specific T cells and durable immunomodulation of gluten-specific CD4+ T cells Patient-reported outcomes indicated dose-dependent reduction of symptoms following a …
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
GlobeNewswire
·
May 6, 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025 EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients Ph2b trial in IBS-C initiating in H2 2025 to …